Finding New Drug Targets Through Disease Differences: AstraZeneca and insitro Sign AI Research Collaboration
A $40 million upfront payment supports drug discovery starting with human and cellular data. The collaboration targets MASH and cardiomyopathy, but whether disease clues identified by AI can translate into effective therapies still requires experimental and clinical validation.